Stevenage Bioscience Catalyst is a renowned hub for life sciences in the UK and is recognised as being on par with other established EU clusters specialising in cell and gene therapy.
Read more about how their exciting developments and opportunities for collaboration is making them a centre for excellence.
- PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments for millions of women worldwide.
Oxford, UK, 29 June 2023 – PrecisionLife, a leading techbio company driving precision medicine in complex chronic diseases, announced today a data access agreement with the University of Oxford to license the Oxford Endometriosis Gene (OXEGENE) dataset with the aim to develop new personalised treatments for endometriosis patients.
Endometriosis is a chronic disease associated…
Planning Submitted at 4 Brandon Road, Kings Cross
Designed collaboratively with the Kadans in-house team and DMA, the building sits adjacent to the existing 5-10 Brandon Road to provide a range of complimentary spaces.
The proposal at 4 Brandon Road is five storeys of flexible lab space with the addition of basement and roof plant. Designed with adaptability at the core, the floorplates are arranged on a regular grid to minimise vibration and maximise usable space.
The double-height entrance creates a sense of arrival and animates the ground floor accommodation. The…
AMSBIO has published a blog about Dr. Satoshi Okamoto’s groundbreaking research on the production of induced pluripotent stem cells (iPSC)-derived liver organoids, and their significant potential in clinical research trials.
The primary objective of Dr. Okamoto's research program at the Yokohama City University Graduate School's Department of Regenerative Medicine was to achieve large-scale, stable production of clinical-grade liver organoids. These organoids have the potential to revolutionize treatment for liver diseases and could be administered to patients with liver diseases as a…
Patents further strengthen Group’s extensive patent portfolio protecting its Arestat™ technology and innovative insulin products, AT278 and AT247
Cambridge, UK, 27 June 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce that the European Patent Office has granted a key patent (EP3518892), protecting novel formulations of the Group’s proprietary insulin products, AT278 and AT247. In addition, the China National Intellectual Property Administration has granted a further patent (CN110582285)…
Cambridge, UK, June 22, 2023 – Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, today announced that it unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate, at the Antibody Industrial Symposium in Tours, France, 22-23 June 2023.
ATLX-1088 is a potential first-in-class human antibody targeting CD33, a cell surface protein which is thought to have a key role in Alzheimer’s disease. Studies have found that higher expression of CD33 is associated with more advanced…
- Data presented at the American Diabetes Association 83rd Scientific Sessions
- AT247 delivers significantly accelerated insulin absorption and early exposure (PK profile) compared with NovoLog® and Fiasp®
- Further supports potential to enable more effective disease management for people with Type I diabetes via fully automated closed loop insulin pump delivery (artificial pancreas)
Cambridge, UK, 26 June 2023. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that positive results from its second Phase…
VOTE NOW
We are delighted to announce the following companies as finalists in our BioNewsRound Award 2023.
Astex - Astex hails trials success of superdrug that saves lives and cuts recurrence risk for thousands of breast cancer patients
AstraZeneca - AstraZeneca and Quell Therapeutics line up $2.85bn alliance
Macomics - Macomics and Ono Pharmaceutical partner to discover and develop macrophage-targeting antibody therapy
PharmEnable - PharmEnable Closes $7.5M Financing led by MP Healthcare to Develop Next Generation of Small Molecule Drugs to Treat Cancer and…
Discover how four seperate developments are making their mark in history at Norwich Research Park following a recent announcement from Anglia Innovation Partnership CEO, Roz Bird, at the 'Innovation in the East of England' event. Read more...
The news article shares insights into:
The Genetic Technology (Precision Breeding) Bill
The results of a study 'Life Science: beyond Human Health' launched by the Government Office for Science.
£164m of investment announced by the BBSRC.
A major investment from UKRI in plant and microbial research hub, totalling £317m over ten years…